Skip to content
ApprovedFDA approved

Methyltestosterone

Orally taken, modified testosterone steroid; a medicine for hormone deficiency, but it puts heavy strain on the liver; banned in sport.

Available at

The links above are labelled third-party affiliate links. MolekulaX does not sell and does not verify product quality.

Methyltestosterone vial

DETAILED OVERVIEW

What is Methyltestosterone?

Methyltestosterone is a modified version of testosterone that can be taken by mouth, the first steroid of this kind, known since 1935. In the United States it was approved as a prescription medicine to treat male hypogonadism, a lack of sex hormones (sold as Android, Methitest and Testred); it is not registered in Hungary or Poland. In bodybuilding it is now considered obsolete.

The modification puts heavy strain on the liver: it can cause cholestatic liver damage (with blocked bile flow) and jaundice, and with long use a risk of liver tumors; together with alcohol, paracetamol or other liver-harming substances it can even be fatal. It also converts into an estrogen, and the substance formed has a stronger estrogen effect than usual, so enlarged male breast tissue and water retention are common. It worsens cholesterol values and shuts down the body's own testosterone production; in women it causes partly irreversible masculinization, and it must not be used in pregnancy. WADA bans it year-round.

Mechanism

Androgen receptor stimulator; works by mouth; converts to estrogen

Anabolic:Androgenic

100:50

Half-life

4 hours (oral)

Onset

1 h (oral, sublingual too)

Legal status

FDA Rx (Android, Methitest, Testred), Schedule III

Data console

Lab data

Androgenic:Anabolic100:50
AR bindingModerate AR affinity (~50-60% vs testosterone in vitro).
Active half-life4 h
Detection windowMethyltestosterone metabolites urinary 4-6 weeks (WADA-accredited GC-MS/LC-MS/MS).
AromatizationYes – CYP19 substrate, metabolite 17α-methylestradiol (paradoxically stronger estrogen effect than plain E2 due to metabolic resistance); clinically high gynecomastia risk (Pope-Kanayama 2014 PMID 24423981)
HepatotoxicityHigh – 17α-methyl group causes cholestatic hepatotoxicity, ALT/AST 3-5x rise common at 4+ week cycle, DILI case-reported (Westaby 1980 PMID 6109024, Hartgens-Kuipers 2004 PMID 15233599)

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Hepatotoxicity: the 17α-methyl group causes cholestatic liver injury with ALT/AST elevation, rarely cholestatic jaundice and peliosis hepatis, and long-term risk of hepatic adenoma/carcinoma.
  • Strong, atypical estrogenic effect: aromatizes to 17α-methylestradiol which resists metabolic inactivation, causing frequent gynecomastia and water retention even at low doses; aromatase inhibitors work poorly, only a SERM blocks it.
  • Adverse lipid profile and cardiovascular strain: lowered HDL, raised LDL, blood-pressure increase from water retention, and elevated atherosclerotic risk over the long term.
  • HPTA suppression and reduced fertility: inhibition of endogenous testosterone, LH and FSH, testicular atrophy and lowered sperm count, which without PCT can lead to prolonged hypogonadism.
  • Androgenic side effects: acne, oily skin, androgenetic hair loss in predisposed men, prostate stimulation and PSA elevation in older men.
  • Virilization in women: deepened voice, increased body hair, clitoral enlargement and menstrual disturbances, partly irreversible.
  • Fluid retention and electrolyte disturbance (sodium and water retention), edema, mood swings and increased irritability.

Contraindications · 7

  • Any pre-existing liver disease or abnormal liver function: an absolute contraindication due to the 17α-methyl structure.
  • Prostate cancer or male breast cancer, and any known or suspected androgen-dependent tumor.
  • Pregnancy and breastfeeding: causes fetal virilization (teratogenic) and is contraindicated while nursing.
  • Severe cardiac, renal or hepatic insufficiency, because fluid retention can precipitate decompensation.
  • Untreated or poorly controlled hypertension, due to further blood-pressure rise from water retention.
  • Concurrent hepatotoxic load: alcohol, paracetamol, NSAIDs or other 17α-alkylated oral AAS together (additive, potentially fatal liver injury).
  • Anticoagulant (warfarin) therapy: AAS potentiate the anticoagulant effect, contraindicated without close INR monitoring due to bleeding risk.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about Methyltestosterone?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.